A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease

NCT02963350 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

CLN2 Disease

Interventions

DRUG: BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)

Sponsor

BioMarin Pharmaceutical